<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796623</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3616-II-01</org_study_id>
    <nct_id>NCT04796623</nct_id>
  </id_info>
  <brief_title>A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer</brief_title>
  <official_title>A Open-label, Multicenter Phase II Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate&#xD;
      the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects&#xD;
      with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort&#xD;
      1 and Cohort 2. Each cohort will enroll 30-60 cases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) assessed by investigator</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>PFS defined as the time from first dose until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Baseline up to 24 months]</time_frame>
    <description>OS defined as the time from first dose to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The time when the participants first achieved complete or partial remission to disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HR-positive, HER2-negative Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TQB3616 capsules combined with fulvestrant injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3616 capsules 180 mg given orally, once daily in 28-day cycle. Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3616 capsules</intervention_name>
    <description>TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.</description>
    <arm_group_label>TQB3616 capsules combined with fulvestrant injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant injection</intervention_name>
    <description>Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.</description>
    <arm_group_label>TQB3616 capsules combined with fulvestrant injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Understood and signed an informed consent form. 2.Eastern Cooperative Oncology Group&#xD;
             (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months. 3.&#xD;
             Histopathologically confirmed HR positive and HER2 negative advanced or metastatic&#xD;
             breast cancer. 4.Cohort 1: patients had received ≤1 line of treatment. 5.Cohort 2:&#xD;
             patients had not previously received systemic antitumor therapy. 6.Has at least one&#xD;
             measurable lesion according to RECIST1.1 criteria. 7.Adequate laboratory indicators.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Concomitant disease and medical history:&#xD;
&#xD;
               1. Has other malignant tumors within 3 years;&#xD;
&#xD;
               2. Has multiple factors affecting oral medication;&#xD;
&#xD;
               3. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy;&#xD;
&#xD;
               4. Has active or uncontrolled severe infections before the first dose;&#xD;
&#xD;
               5. Cirrhosis, active hepatitis#&#xD;
&#xD;
               6. Have a history of immunodeficiency; 2. Tumor-related symptoms and treatment:&#xD;
&#xD;
               1. Has central nervous system metastases (CNS) and/or cancerous meningitis or&#xD;
                  leptomeningeal carcinomatosis;&#xD;
&#xD;
               2. Had received chemotherapy within 3 weeks prior to the first dose, and had&#xD;
                  received radiotherapy , hormone therapy, or other anti-tumor therapy within 2&#xD;
                  weeks prior to the first dose;&#xD;
&#xD;
               3. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring&#xD;
                  recurrent drainage procedures.&#xD;
&#xD;
                  3. Has known to be allergic to Fulvestrant injection , TQB3616 or any excipient.&#xD;
&#xD;
                  4. Has Participated in other clinical trials within 4 weeks before first dose. 5.&#xD;
                  According to the judgement of the investigators, there are other factors that may&#xD;
                  lead to the termination of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zefei Jiang, Doctor</last_name>
      <phone>010-66947171</phone>
      <email>jiangzefei@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Zefei Jiang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohua Zeng, Doctor</last_name>
      <email>1340110079@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiaohua Zeng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial Hostipal</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haiyun Huang, Doctor</last_name>
      <email>huangsam68@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Haiyun Huang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Hao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kun Wang, Doctor</last_name>
      <email>gzwangkun@126.com</email>
    </contact>
    <investigator>
      <last_name>Kun Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanxia Shi, Doctor</last_name>
      <email>shiyx@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Yanxia Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weimin Xie, Doctor</last_name>
      <email>dd.xie@qq.com</email>
    </contact>
    <investigator>
      <last_name>Weimin Xie, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunjiang Liu, Doctor</last_name>
      <email>lyj818326@126.com</email>
    </contact>
    <investigator>
      <last_name>Yunjiang Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Affiliated Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, Doctor</last_name>
      <email>sy86298276@163.com</email>
    </contact>
    <investigator>
      <last_name>Qingyuan Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Quzhang Ouyang, Doctor</last_name>
      <email>oyqc_susar@126.com</email>
    </contact>
    <investigator>
      <last_name>Quzhang Ouyang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhai Tang, Doctor</last_name>
      <phone>025-68305758</phone>
      <email>tangjinhai@jsph.org.cn</email>
    </contact>
    <investigator>
      <last_name>Jinhai Tang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Man Li, Doctor</last_name>
      <email>dyeyliman@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Man Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tao Sun, Doctor</last_name>
      <email>lnzlrxnsy@163.com</email>
    </contact>
    <investigator>
      <last_name>Tao Sun, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qun Li, Doctor</last_name>
      <email>liqun@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Qun Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of PLA Air Force Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haichuan Su, Doctor</last_name>
      <email>cntdgcp@163.com</email>
    </contact>
    <investigator>
      <last_name>Haichuan Su, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiao Tong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Ren, Doctor</last_name>
      <email>renyyyyyy@126.com</email>
    </contact>
    <investigator>
      <last_name>Yu Ren, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bing Zhao, Doctor</last_name>
      <email>819502412@qq.com</email>
    </contact>
    <investigator>
      <last_name>Bing Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Shen</last_name>
      <email>zyyx_sp@163.com</email>
    </contact>
    <investigator>
      <last_name>Peng Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

